Mark Pennesi, M.D., Ph.D., who leads OHSU's involvement in the trial, center right, looks on as staff at Oregon Health & Science University's Casey Eye Institute perform the first-ever in vivo CRISPR gene edit procedure for the BRILLIANCE clinical trial. The study uses the gene-editing technology CRISPR to repair mutations in the CEP290 gene that cause a rare form of inherited blindness called Leber congenital amaurosis type 10. The trial is sponsored by Allergan plc. and Editas Medicine. (OHSU/Kristyna Wentz-Graff)
